padcev ejfv - enfortumab vedotin injection, powder, lyophilized, for solution
(Enfortumab Vedotin)Seagen Inc.
Usage: PADCEV treats adult patients with muscle-invasive bladder cancer (MIBC) ineligible for cisplatin, combined with pembrolizumab as neoadjuvant/adjuvant therapy. Also indicated for locally advanced or metastatic urothelial cancer (mUC) in combination or as a single agent after prior treatment.